Company profile
VIROLOGY RESEARCH SERVICES | Virology Research Services
Virology Research Services Limited is a UK company with status active founded in 2018 based in South East England.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNDk0MjE0NGFkaXF6a2N4
Published 09 Sep 2024 11:06
Company registered at Companies House
Virology Research Services was founded by scientists at University College London to share world-leading resources and expertise with industry and academia, aiming to help combat infectious diseases. Our focus is preclinical studies and viral biology, where we provide rigorous, original, and cost-effective solutions to the early stages of R&D. We help companies and academics explore new antiviral treatments, investigate the biology of viral infection, and test pathogen response to treatment.
Virology Research Services provides a range of outsourced virology testing and analysis services.
Virology Research Services (VRS) was awarded a £25k MRC Proximity to Discovery Industry Engagement Fund for knowledge exchange with The Native Antigen Company (TNAC, LINK), a group focused on the expression and purification of viral antigens, and of antibodies targeting viral proteins. Most antibodies against viral proteins, particularly for emerging viruses, tend to be well characterised in biochemical assays; however, a thorough characterisation for immunofluorescence (IF) is often lacking. This represents a concern for scientists interested in image-based applications, who may need to test and optimise several antibodies before identifying a suitable one. Making use of the extensive virology and imaging expertise at VRS, and of the state-of-the-art high-throughput and microscopy facilities at UCL, the aim was to develop high- and low- throughput protocols for different antibodies, validate their specificity across viruses of the same family, and generate informative pictures as a reference. This successful collaboration which resulted in a full characterisation of TNAC's Antibodies and has been reported on the companies website: https://thenativeantigencompany.com/new-immunofluorescence-data-for-flavivirus-antibodies/
Screening anti-viral compounds
1 Sep 2022 to 31 Aug 2026
no public description
